Topical corticosteroids are indicated in pregnant women with skin conditions. However, the evidence of their safety in pregnancy is limited.
Background
Topical corticosteroids are indicated in pregnant women with skin conditions. However, the evidence of their safety in pregnancy is limited.
Objective
To investigate whether maternal exposure to topical corticosteroids results in adverse pregnancy outcomes.
Methods
We used the UK Health Informatics Centre (HIC) Datasets to conduct a population-based retrospective cohort study.
The exposed group were pregnant women aged 15 to 44 years who received one or more dispensed prescriptions for topical corticosteroids at any time during pregnancy. Women having received one or more dispensed prescriptions for any other form (systemic, injection, inhalation, or nasal) of corticosteroids during pregnancy, multiple pregnancy, and pregnancy following assisted reproduction were excluded. For each exposed women, we selected up to three unexposed pregnant women not having any dispensed prescription for any form of corticosteroids during pregnancy by matching for maternal age and calendar year of pregnancy.
We compared pregnancy outcomes (including orofacial cleft, preterm delivery, fetal death, low Apgar score, and mode of delivery) between the two groups by calculating the risk ratios (RRs) and 95% confidence intervals (CIs) after adjustment for confounders including previous exposure to topical corticosteroids within one year before pregnancy, maternal comorbidities, and exposure to other medications that may affect pregnancy outcomes (drugs classified as US FDA Pregnancy Risk Category D or X). Stratified analyses based on corticosteroid potency and sensitivity analyses after further adjustment for maternal smoking and socio-economic levels were performed.
Results
We identified 2,658 exposed and 7,246 unexposed women. No associations between maternal topical corticosteroid exposure and pregnancy outcomes [including orofacial cleft, low birth weight (LBW), preterm delivery, fetal death, low Apgar score, and mode of delivery] were found [adjusted risk ratio (RR) 1.85 [95% confidence interval (CI) 0.22-15.20], 0.97 (95% CI 0.78-1.19), 1.14 (95% CI 0.70-1.86), 1.04 (95% CI 0.55-1.98), 0.84 (95% CI 0.54-1.31), and P = 0.760 respectively]. Stratified analyses based on corticosteroid potency and sensitivity analyses did not change the results. An exploratory analysis showed a significantly increased risk of LBW when the dispensed amount of potent/very potent topical corticosteroids exceeded 300 g (adjusted RR 7.49; 95% CI 1. 44-38.83) .
Conclusions
This study reassuringly showed a lack of associations of maternal topical corticosteroid exposure with orofacial cleft, preterm delivery, fetal death, low Apgar score, and mode of delivery. Putting this study and all available evidence together, the risk of LBW appears to correlate with the quantity of topical corticosteroid exposure. Exploratory analysis on the amounts of strong topical corticosteroids and risk of low birth weight
